parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in pdcs	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	7 Parkinson's papers of 2,439	0.73
pathways Reactome	4 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 10158

receipt 10165: TCF4 in dopamine neurons, braak

power: full sample +0.39 (p 0.109, n 18), 95% CI -0.09 to +0.73. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.30 (p 0.221, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.258, n 18). could be the mix.
skeptic: leave-one-out range +0.32 to +0.56, sign flips 0; without severely affected donors +0.39 (p 0.109, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TCF4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10164: TCF4 in oligodendrocytes, braak

power: full sample +0.21 (p 0.393, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.21 (p 0.393, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.14 (p 0.573, n 18). could be the mix.
skeptic: leave-one-out range +0.10 to +0.39, sign flips 0; without severely affected donors +0.21 (p 0.393, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TCF4 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts